Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters











Language
Publication year range
1.
Prog Neuropsychopharmacol Biol Psychiatry ; 36(1): 29-33, 2012 Jan 10.
Article in English | MEDLINE | ID: mdl-21925231

ABSTRACT

The purpose of this study was to determine the effects of alstonine, an indole alkaloid with putative antipsychotic effects, on working memory by using the step-down inhibitory avoidance paradigm and MK801-induced working memory deficits in mice. Additionally, the role of serotonin 5-HT2A/C receptors in the effects of alstonine on mouse models associated with positive (MK801-induced hyperlocomotion), negative (MK801-induced social interaction deficit), and cognitive (MK801-induced working memory deficit) schizophrenia symptoms was examined. Treatment with alstonine was able to prevent MK801-induced working memory deficit, indicating its potential benefit for cognitive deficits now seen as a core symptom in the disease. Corroborating previously reported data, alstonine was also effective in counteracting MK801-induced hyperlocomotion and social interaction deficit. Ritanserin, a 5-HT2A/C receptor antagonist, prevented alstonine's effects on these three behavioral parameters. This study presents additional evidence that 5-HT2A/C receptors are central to the antipsychotic-like effects of alstonine, consistently seen in mouse models relevant to the three dimensions of schizophrenia symptoms.


Subject(s)
Antipsychotic Agents/therapeutic use , Receptor, Serotonin, 5-HT2A/physiology , Receptor, Serotonin, 5-HT2C/physiology , Secologanin Tryptamine Alkaloids/therapeutic use , Animals , Antipsychotic Agents/pharmacology , Dizocilpine Maleate/toxicity , Hyperkinesis/chemically induced , Hyperkinesis/drug therapy , Male , Memory Disorders/chemically induced , Memory Disorders/drug therapy , Mice , Secologanin Tryptamine Alkaloids/pharmacology
2.
Phytomedicine ; 18(4): 327-33, 2011 Feb 15.
Article in English | MEDLINE | ID: mdl-20739160

ABSTRACT

UNLABELLED: Alzheimer's disease (AD) is expected to affect more than 22 million people worldwide by 2025, causing devastating suffering and enormous costs to families and society. AD is a multifactorial disease, with a complex pathological mosaic. In rodents, AD-like dementia can be induced by cerebral microinjection of Aß peptide, leading to amyloid deposits, amnesia and various features of neurodegeneration. Marapuama (Ptychopetalum olacoides) is regarded as a "brain tonic" in the Amazon region and shows a nootropic profile in rodents. AIM OF THE STUDY: Because a specific extract (POEE) of Marapuama was shown to possess promnesic and anti-amnesic properties, the aim of this study was to verify if POEE is also effective against Aß(1-42)-induced cognitive deficit in mice. Additionally, Aß deposits (Congo red), GFAP immunoreactivity (immunohistochemistry), and neurodegenerative changes in the hippocampal pyramidal layer (Nissl) were examined as measures of Aß(1-42)-induced neurodegeneration. MATERIALS AND METHODS: CF1 mice were subjected to the experimental Alzheimer model with the Aß(1-42) i.c.v. administration. The effects of POEE 800 mg/kg were evaluated over 14 consecutive days of treatment. RESULTS: The data show that 14 days of oral treatment with POEE (800 mg/kg) was effective in preventing Aß-induced cognitive impairment, without altering the levels of BDNF and with parallel reductions in Aß deposits and astrogliosis. CA1 hippocampus loss induced by Aß(1-42) was also diminished in POEE-treated mice. CONCLUSION: This study offers evidence of functional and neuroprotective effects of two weeks treatment with a Ptychopetalum olacoides extract against Aß peptide-induced neurotoxicity in mice. Given the multifactorial nature of neurodegeneration, the considerable potential for an AChE inhibitor displaying associated neuroprotective properties such as here reported warrants further clinic evaluation.


Subject(s)
Cognition Disorders/drug therapy , Nerve Degeneration/drug therapy , Nootropic Agents/pharmacology , Olacaceae/chemistry , Phytotherapy , Plant Extracts/pharmacology , Alzheimer Disease/drug therapy , Amyloid beta-Peptides/pharmacology , Animals , Brain/drug effects , Dementia/drug therapy , Disease Models, Animal , Disease Progression , Male , Mice , Neuroglia/pathology , Nootropic Agents/therapeutic use , Peptide Fragments/pharmacology , Plant Extracts/therapeutic use , Plants, Medicinal/chemistry
3.
Phytomedicine ; 17(3-4): 248-53, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19682881

ABSTRACT

With the recognition that high levels of sustained stress are associated with the natural course of countless illnesses, effective anti-stress agents have gained importance. Improved endurance to particularly stressful periods is one of the medicinal claims for Marapuama (Ptychopetalum olacoides Bentham, PO), a popular Amazonian herbal. The purpose of this study was to evaluate if PO possesses anti-stress properties. To this end, an extract from PO (POEE) was evaluated on anxiety and glucose levels in mice submitted to the unpredictable chronic mild stress (UCMS) paradigm. POEE did not present anxiolytic effects, but was able to prevent (p<0.01) the UCMS-induced anxiety as assessed by the light/dark test (time spent in the lit area, POEE 100 and 300mg/kg 235.9+/-20.6s and 250.4+/-17.4s, respectively, compared to DMSO 104.7+/-24.4s). Likewise, although POEE did not induce noticeable effects on glycemia, it effectively (p<0.01) prevented the UCMS-induced hyperglycemia (POEE 100 and 300mg/kg 106.4+/-6.7mg/dl and 107.3+/-3.3mg/dl, respectively, compared to DMSO 134.6+/-5.9mg/dl). Additionally, POEE (50-200mg/kg i.p. and 800mg/kg p.o.) significantly (p<0.01 and p<0.05, respectively) increased the time to hypoxia-induced convulsion (by 38%, 51%, 59% and 27%, respectively for i.p. and p.o. treatments). The data indicate that POEE counteracts some of the effects brought about by chronic stress. This study combined with the identified antioxidant and neuroprotective properties, as well as the claimed benefits associated with stressful periods suggest that Ptychopetalum olacoides (Marapuama) might possess adaptogen-like properties.


Subject(s)
Anti-Anxiety Agents/therapeutic use , Anxiety/prevention & control , Hyperglycemia/prevention & control , Olacaceae , Plant Extracts/therapeutic use , Seizures/drug therapy , Animals , Anti-Anxiety Agents/pharmacology , Antioxidants/pharmacology , Antioxidants/therapeutic use , Blood Glucose/drug effects , Dimethyl Sulfoxide/pharmacology , Dimethyl Sulfoxide/therapeutic use , Hyperglycemia/etiology , Hypoxia/drug therapy , Light , Male , Mice , Mice, Inbred Strains , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Olacaceae/chemistry , Phytotherapy , Plant Extracts/pharmacology , Plant Roots , Stress, Psychological/prevention & control
4.
Bull World Health Organ ; 70(1): 85-91, 1992.
Article in English | MEDLINE | ID: mdl-1314711

ABSTRACT

Described is the evaluation in Brazil of the immune response of early immunization with trivalent oral poliovirus vaccine (TOPV). A total of 85 normal neonates from São Paulo were assigned one of the following immunization schedules: group A--one dose of TOPV at birth and subsequent doses at 2, 4, and 9 months of age; or group B--one dose of TOPV at 2, 4 and 6 months of age. Blood samples were collected sequentially from the mother at delivery, from the umbilical cord, and from the child at 2, 4, 6, 9 and 12 months of age for assay of poliovirus neutralizing antibodies. Administration of TOPV at birth, in addition to establishing immunity against poliomyelitis at an earlier stage, produced a superior immune response to poliovirus type 3. At the end of the first year, the proportion of susceptible individuals was 3.7% in group A and 25.9% in group B. When immunization against poliomyelitis is started at birth, excellent seroconversion rates are obtained from the third dose onward.


Subject(s)
Antibody Formation , Poliovirus Vaccine, Oral/immunology , Poliovirus/immunology , Age Factors , Antibodies, Viral/isolation & purification , Humans , Immunization Schedule , Infant , Infant, Newborn , Poliovirus Vaccine, Oral/administration & dosage
5.
Arch Int Physiol Biochim ; 95(4): 329-32, 1987 Nov.
Article in English | MEDLINE | ID: mdl-2453176

ABSTRACT

In the rat, the effects of an atrial natriuretic factor (ANF) (Rat, 8-33 Peninsula Lab) on body water distribution have been evaluated. The ANF administration to nephrectomized animals produced a decrease in plasma volume and a slight increase in haematocrit and in plasma albumin concentration. No modifications were observed in total and intracellular water. The fluid efflux from the capillaries appeared to be located in the interstitial space. These results suggest that ANF could regulate plasma volume and systemic blood pressure, concurrently with its other known effects.


Subject(s)
Atrial Natriuretic Factor/physiology , Body Water/physiology , Water-Electrolyte Balance , Animals , Blood Pressure , Blood Volume , Extracellular Space/physiology , Hematocrit , Male , Nephrectomy , Rats
6.
Proc R Soc Med ; 70 Suppl 1: 24-8, 1977.
Article in English | MEDLINE | ID: mdl-122643

ABSTRACT

Results are presented of treatment with miconazole, orally and intravenously, in patients with paracoccidioidomycosis. Twenty-eight male patients aged from 34 to 66 years and exhibiting various clinical forms of the disease were studied. Twenty-five came from endemic areas in north east Argentina (Chaco, Formosa, Misiones, Corrientes and northern Santa Fe) and the remaining three from Paraguay. Twenty patients were engaged in agricultural work or at woodmills. single or multiple lesions were observed in 24 cases. Thirteen were suffering from infection of the larynx and in two of them a tracheotomy was necessary. Twenty-three showed pulmonary lesions on X-rays. Twelve had ganglionic lesions, eight had cutaneous lesions and one patient had osteoarthritis of the knee. One patient had hepatomegaly which was unrelated to chronic alcoholism. Fourteen patients had received previous treatments such as sulphonamides and amphotericin B (7 cases); sulphonamides (3), sulphonamides and the combination sulfamethoxazole + trimethoprim (3), and one patient had received all three medications. All patients had relapsed before starting miconazole therapy. Diagnosis was established by the presence of P. brasiliensis in all cases, recovered either from cutaneous or mucosal biopsy samples or from the sputum. Complement fixation tests were positive in all patients at the onset of the treatment and the immunodiffusion reactions showed precipitation bands in 27/28 patients. Skin tests with P. brasiliensis antigens proved to be positive in 18 cases and negative in 10. The erythrocyte sedimentation rate was markedly accelerated in 22 patients (greater than 20 mm in the first hour).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Miconazole/therapeutic use , Paracoccidioidomycosis/drug therapy , Administration, Oral , Adult , Aged , Drug Administration Schedule , Humans , Injections, Intravenous , Male , Miconazole/administration & dosage , Middle Aged , Tablets
7.
Arch. virol ; 54: 255-257, 1977.
Article in English | Sec. Est. Saúde SP, SESSP-IPACERVO | ID: biblio-1059810
SELECTION OF CITATIONS
SEARCH DETAIL